The freshest thing today is a stock move, not a science one. Shares of Compass Pathways, a company testing a psychedelic for depression, rose about 4.3% — but on no new results and no ruling. Meanwhile MindMed, another psychedelic company, slipped about 4%. Beneath the market wiggles, the bigger conversation is about a man President Trump has picked to help run the FDA — the agency that decides which medicines Americans can use. This nominee is closely tied to the podcaster Joe Rogan and has publicly cheered psychedelics. His confirmation hearings — the sessions where senators grill him before he can take the job — are expected within about ten weeks. And on the treatment side, a Brazilian trial called SAVE is expected to report results around November on whether a fast-acting drug can quickly ease suicidal thoughts.
Here is the current beneath the news. A loud, camera-friendly champion does not speed up a medicine. The FDA still needs solid proof before it approves anything. So the honest read is that MDMA — a drug being studied for the deep wound of trauma — is unlikely to get a fresh green light before November, because the company still owes the agency new confirming evidence. And the more famous the nominee becomes, the more likely a major newspaper digs into his psychedelic ties and forces him to sound cautious, not bold. That sounds like a setback. It isn't. Careful, boring, evidence-first review is exactly what turns a fringe hope into a real medicine that doctors trust and insurance pays for. The slow door is the door that stays open.
The other quiet mover is Congress. Advocates for veterans are expected to attach a psychedelic research measure to the big yearly defense bill — the vehicle where veteran priorities usually get bolted on. Whether it survives is unknown. But it is being offered, and that alone keeps the veteran path alive on two tracks at once: national law and individual states.
For the real people inside this, the felt reality is patience stretched thin. A veteran who has tried every approved pill for post-traumatic stress — the crushing weight left behind by trauma — reads about a famous FDA pick and dares to hope, then reads the fine print and deflates. A family in Brazil watching a loved one drown in suicidal thoughts is waiting on that November trial to see if fast relief is real. None of them got their answer today. But the most honest good news is this: the systems that protect them are working slowly on purpose. When the yes finally comes, it will be one that lasts — a medicine, not a headline. That is worth the wait, even when the waiting hurts.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The medicine is older than the fear. The healing is older than the wound.
70%
MDMA therapy drug application stays stuck at US regulator
Lykos Therapeutics wants to resubmit its application to get MDMA-assisted therapy approved as a treatment in the US. The prediction is that the FDA (the US Food and Drug Administration, the country's drug regulator) won't formally accept that resubmission before November 2026. This matters because millions of people with PTSD (post-traumatic stress disorder) are waiting for a new treatment option.
→ The MDMA therapy application is almost certainly still stuck in limbo come November 2026, because new supporting data — which the FDA needs — simply isn't there yet.
Resolves: 2026-11-15 · USA
REGULATORY
the precise call ▾
No new Lykos/MDMA resubmission acceptance is announced by FDA before November 2026 despite nominee hype.. A leadership nominee cannot compress the review of an NDA lacking new confirmatory data. The absence of MDMA data signals today confirms nothing is imminent.
66%
FDA nominee's psychedelic links force him to slow down publicly
The person nominated to run the FDA (the US drug regulator) is publicly known as a supporter of psychedelic medicines. The prediction is that this connection will generate so much scrutiny — press coverage, Senate questions — that he'll have to publicly pull back from that advocacy role rather than use his position to fast-track approvals. Regulators under the spotlight tend to become more cautious, not bolder.
→ The FDA nominee's psychedelic connections are more likely to become a political liability that slows things down than a springboard that speeds approvals up.
Resolves: 2026-11-23 · USA
REGULATORY
the precise call ▾
The Rogan-aligned FDA nominee triggers a conflict-of-interest story forcing public moderation, not accelerated approval.. Consensus of 2 agents: fda_reviewer, journalist. 1 dissenting.
66%
FDA nominee publicly softens his psychedelic advocacy before mid-October
The person being considered to lead the FDA (the US drug regulator) has been an enthusiastic public promoter of psychedelic medicines. The prediction is that by mid-October 2026, facing Senate confirmation hearings and press scrutiny, he'll publicly dial back that enthusiasm — saying things like 'I'll follow the science' rather than championing these drugs. Politicians and nominees almost always moderate their most controversial positions when they need votes and credibility.
→ By mid-October 2026, expect the FDA nominee to stop sounding like a psychedelic advocate and start sounding like a cautious regulator — because that's what confirmation politics demands.
Resolves: 2026-10-20 · USA
REGULATORY
the precise call ▾
The Trump FDA nominee will make a public statement moderating his psychedelic-promotion stance during confirmation-related press by mid-October 2026.. Nominees under scrutiny retreat toward institutional caution. My colleagues protect the agency's credibility above ideology; a Rogan-linked reformer gets pushed to reassure Senate reviewers.
68%
Brazilian trial shows ketamine quickly reduces suicidal crisis
A large real-world clinical trial in Brazil called SAVE is testing whether esketamine — a nasal-spray version of the anesthetic ketamine, already approved for depression — can quickly reduce the urge to attempt suicide in people in crisis. Results are expected around November 2026, and the prediction is that the numbers will show a clear, meaningful benefit. This could change emergency mental health care globally.
→ A major Brazilian trial is very likely to confirm by November 2026 that ketamine can rapidly reduce suicidal thinking — which could reshape how hospitals handle mental health emergencies.
Resolves: 2026-11-30 · Global
CLINICAL
the precise call ▾
The SAVE Brazilian esketamine trial reports a statistically significant acute anti-suicidal effect at topline (~Nov 2026).. Acute anti-suicidal signals for esketamine replicate consistently across trials. Pragmatic municipal design favors real-world effect detection. The data is undeniable — delay costs lives.
68%
Major news outlet investigates FDA nominee's psychedelic business ties
The person nominated to lead the FDA (the US drug regulator) has vocal, public connections to the psychedelic therapy world — including ties to podcaster Joe Rogan's media universe. The prediction is that a major news organization will publish an investigation into potential conflicts of interest before his confirmation process wraps up. When a regulator has financial or promotional ties to the very industry they'd oversee, it's a serious public accountability question.
→ Expect a major investigative story questioning whether the FDA's potential new boss can fairly regulate an industry he's publicly championed.
Resolves: 2026-10-25 · USA
CULTURE
the precise call ▾
A major outlet publishes a conflict-of-interest investigation into the FDA nominee's psychedelic ties before his confirmation resolves.. A Rogan-backed psychedelic architect running FDA is irresistible copy. The story forces public moderation, not acceleration. Scrutiny is the predictable press response.